Evidence map›Paper›PMID 38033732›Full record

ArticleRSC chemical biology2023

Biotransformation-coupled mutasynthesis for the generation of novel pristinamycin derivatives by engineering the phenylglycine residue.

Oliver Hennrich, Leoni Weinmann, Andreas Kulik, Karen Harms, Philipp Klahn, Jung-Won Youn, Frank Surup, Yvonne Mast

Abstract read
In one paragraph

Article in RSC chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Oliver HennrichDepartment Bioresources for Bioeconomy and Health Research, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstraße 7B 38124 Braunschweig Germany yvonne.mast@dsmz.de.
Leoni WeinmannInstitute of Microbiology, University Stuttgart, Allmandring 31 D-70569 Stuttgart Germany.
Andreas KulikDepartment Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, Faculty of Science, University of Tübingen, Auf der Morgenstelle 28 D-72076 Tübingen Germany.ORCID https://orcid.org/0000-0002-6914-7313
Karen HarmsMicrobial Drugs Department, Helmholtz-Centre for Infection Research 38124 Braunschweig Germany.ORCID https://orcid.org/0000-0002-5867-0846
Philipp KlahnDivision of Organic and Medicinal Chemistry, Department of Chemistry and Molecular Biology, University of Gothenburg, Kemigården 4 412 96 Göteborg Sweden.ORCID https://orcid.org/0000-0003-4713-2345
Jung-Won YounInstitute of Microbiology, University Stuttgart, Allmandring 31 D-70569 Stuttgart Germany.
Frank SurupMicrobial Drugs Department, Helmholtz-Centre for Infection Research 38124 Braunschweig Germany.ORCID https://orcid.org/0000-0001-5234-8525
Yvonne MastDepartment Bioresources for Bioeconomy and Health Research, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstraße 7B 38124 Braunschweig Germany yvonne.mast@dsmz.de.ORCID https://orcid.org/0000-0003-3099-5777

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Streptogramins are the last line of defense antimicrobials with pristinamycin as a representative substance used as therapeutics against highly resistant pathogenic bacteria. However, the emergence of (multi)drug-resistant pathogens renders these valuable antibiotics useless; making it necessary to derivatize compounds for new compound characteristics, which is often difficult by chemical

Identifiers

PMID38033732
PMCPMC10685826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.